
Advancing Respiratory Medicine
The MediPines AGM100® provides fast, accurate, and non-invasive assessments of pulmonary gas exchange to improve diagnostic decisions.
Global Respiratory Disease
We are the market leader in non-invasive, rapid assessment of pulmonary gas exchange.
COVID-19: 676 million people
Pneumonia: 450 million people annually
Asthma: 350 million people
COPD: 200 million people
Improve Patient Outcomes
Non-Invasive
Achieve over 90% patient compliance with our breathing circuit.
High Precision
PaO2 accuracy of over 95% compared to traditional ABG.
Single Operator
No labs, blood draw or complex set up. No calibration required.
Multi-parameter
In less than 2 minutes, we provide 12 cardiopulmonary diagnostic parameters
Use Cases
Improve diagnostic decisions across the continuum of care. From the emergency room to out-patient clinics, our device has helped patients receive faster, more accurate diagnosis.
How the AGM100 Works
Gas exchange measurement in under 90 seconds
Award winning medical device, trusted by doctors and patients
AGM100 selected by WHO
Medical Innovation
“Innovative technologies are accelerating access to healthcare everywhere, we must ensure that they (innovative technologies) are readily available in all health facilities, fairly priced and quality-assured”
- WH0 Assistant Director General
Medical Design Award
AGM100 receives special designation
MediPines AGM100® device has been awarded the prestigious MDEA Award for Testing and Diagnostic Products in the 2021 Medical Design Excellence Awards




News and Updates
Our Latest Publications
Read about the latest publications and learn the science behind the AGM100.